You are here

Article Text

Article menu

This article has a correction. Please see:

Download PDFPDF
Letter
Complete regression of advanced HCC with long acting octreotide
  1. J T Siveke1,
  2. C Folwaczny2,
  3. C Herberhold3
  1. 1Department of Internal Medicine II, Technical University of Munich, Munich, Germany
  2. 2Medizinische Klinik und Poliklinik, Klinikum der Universität, Munich, Germany
  3. 3Department of Surgery Innenstadt, Munich, Germany
  1. Correspondence to:
    C Folwaczny, Medizinische Klinik und Poliklinik, Klinikum der Universität, Numßbaumstr. 20, 80336 München, Germany;
    Christian.Folwaczny{at}medinn.med.uni-muenchen.de

https://doi.org/10.1136/gut.52.10.1531-a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Various therapeutic approaches for unresectable hepatocellular carcinoma (HCC) have been suggested in recent years. However, major advances concerning tumour regression or patient survival were not achieved. A few trials have assessed the effect of the somatostatin analogue octreotide in advanced HCC with divergent results.1,2 The latter might be due to expression of somatostatin receptor type 2 (SSTR2) in some but not all patients with HCC.3,4 Herein we describe a patient with advanced HCC who was treated with long acting octreotide, which resulted in complete and prolonged regression of the tumour.

    The patient was diagnosed with HCC after a suspect nodule …

    View Full Text